

## Number of shares and votes in Ascelia Pharma AB

During April 2021, the number of common shares increased by 5,000,000 as a result of the completed directed new share issue. The number of C-shares also increased in April by 397,641 following a directed share issue and repurchase of these shares (the C-shares are held by Ascelia Pharma). The issue of C-shares is linked to the company's share saving program (LTI 2020), which was resolved by the Annual General Meeting on May 6, 2020.

As of April 30, 2021, the number of shares amounts to 34,576,448, of which 33,668,262 are common shares with one vote per share and 908,186 are C-shares with one tenth of a vote each. The total number of votes in the company amounts to 33,759,080.6.

### Contacts

---

Magnus Corfitzen, CEO  
Email: [moc@ascelia.com](mailto:moc@ascelia.com)  
Tel: 46 735 179 118

Mikael Widell, Head of IR & Communications  
Email: [mw@ascelia.com](mailto:mw@ascelia.com)  
Tel: +46 703 11 99 60

*This information was submitted for publication, through the agency of the contact persons set out above.*

*This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-04-30 15:15 CEST.*

## About Us

---

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit <http://www.ascelia.com>.

### About Mangoral

Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

### About Oncoral

Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.

## Attachments

---

[Number of shares and votes in Ascelia Pharma AB](#)